Press

Pharmala Biotech: CEO Letter To Shareholders

Jun 7 • 5 min read

Over the past 48 hours, a large number of shareholders have reached out to me for my thoughts on the recent FDA Advisory Committee Meeting convened to discuss the Lykos Therapeutics application for New Drug Approval for Midomafetamine (MDMA). As most of you know by now, the committee overwhelmingly voted that there was not enough…

Psych Capital Changes Name To Shortwave Life Sciences

Jun 7 • 1 min read

Shortwave Life Sciences PLC – London-based drug development for mental health – Changes name from Psych Capital following the acquisition of Shortwave Pharma Inc last year. Says the new name reflects its focus on mental health, particularly eating disorders. This includes psychedelics-based therapies. “Eating disorders, including anorexia nervosa, bulimia nervosa, and binge-eating disorder, represent a…

Lobe Sciences Announces Update

Jun 5 • 3 min read

VANCOUVER, British Columbia, June 04, 2024–(BUSINESS WIRE)–Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) (“Lobe” or the “Company”), a biopharmaceutical company focused on developing transformative medicines to treat diseases with unmet medical needs and rare diseases announced the evaluation of strategic alternatives to improve shareholder value. Lobe Sciences has been exploring strategies to enhance shareholder value….

Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jun 5 • 4 min read

SARASOTA, FL, June 05, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into definitive agreements for the purchase and sale of 917,432 shares of…

Awakn Life Sciences Announces Closing of Tranche of Private Placement

Jun 4 • 2 min read

Toronto, Ontario–(Newsfile Corp. – June 4, 2024) – Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn” or the “Company”) a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder, is pleased to announce that, further to its press releases dated April 3, 2024, and April…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441